Chemcon Q2 FY23 revenue down 5.4%; Profit down 46.6%
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
Q2 FY23 business performance has been slow primarily due to lower volume offtake from pharmaceutical manufacturers
Reinforcing GLC’s commitment to sustainable processing in pharmaceutical chemistry
Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side
Periodic community awareness program through Aster’s DM Healthcare’s visual media and social media platforms and implementing TB control activity through Aster Pharmacies across South India
DKSH has signed an agreement to acquire two ear care brands from Noru Pharma for Australia, New Zealand, and selected markets in Asia.
Availability of pharmaceutical-grade materials with broad API compatibility key to advancing drug delivery solutions
Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease
The company has partnered with Neethi, a Kerala state cooperative consumers federation limited company, to run this program in Kerala
The capital expansion program commenced in June 2022 and is expected to complete in 2024
GlobalData’s ‘Pharmaceutical Intelligence Center’ observes that India is still in the nascent stage of developing these potential therapies as currently only four cell/gene therapy molecules are being developed in the country.
Subscribe To Our Newsletter & Stay Updated